Filing Details
- Accession Number:
- 0001209191-23-012672
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-24 16:06:38
- Reporting Period:
- 2023-02-22
- Accepted Time:
- 2023-02-24 16:06:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-02-22 | 129 | $291.84 | 68,576 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-22 | 300 | $292.86 | 68,276 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-22 | 1,378 | $294.29 | 66,898 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-22 | 394 | $295.38 | 66,504 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-22 | 200 | $296.31 | 66,304 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $291.84 (range $291.17 to $292.03).
- Open market sales reported on this line occurred at a weighted average price of $292.86 (range $292.44 to $293.37).
- Open market sales reported on this line occurred at a weighted average price of $294.29 (range $293.83 to $294.82).
- Open market sales reported on this line occurred at a weighted average price of $295.38 (range $294.83 to $295.72).
- Open market sales reported on this line occurred at a weighted average price of $296.31 (range $296.20 to $296.41).
Billionaire Hedge Funds
